Compare · PFE vs THRN
PFE vs THRN
Side-by-side comparison of Pfizer Inc. (PFE) and Thorne Healthtech Inc. (THRN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both PFE and THRN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $304.95B, about 1184.4x THRN ($257.5M).
- PFE has hit the wire 10 times in the past 4 weeks while THRN has been quiet.
- PFE has more recent analyst coverage (25 ratings vs 6 for THRN).
- Company
- Pfizer Inc.
- Thorne Healthtech Inc.
- Price
- $26.98+1.20%
- $10.20+0.00%
- Market cap
- $304.95B
- $257.5M
- 1M return
- -1.21%
- -
- 1Y return
- +17.13%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 10
- 0
- Recent ratings
- 25
- 6
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities
Latest THRN
- SEC Form SC 13G/A filed by Thorne Healthtech Inc. (Amendment)
- SEC Form 15-12G filed by Thorne Healthtech Inc.
- Varma Saloni S. returned 581,643 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Mckenna Thomas P. returned 1,172,227 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Mccamy William C. returned 589,804 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Kauss Sarah M returned 105,874 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Jacobson Paul F returned 3,928,411 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Braglia Riccardo returned 5,424,550 shares to the company (SEC Form 4)
- Varma Saloni S. covered exercise/tax liability with 3,454 shares, decreasing direct ownership by 4% to 81,643 units (SEC Form 4) (Amendment)
- Mckenna Thomas P. covered exercise/tax liability with 11,257 shares, decreasing direct ownership by 1% to 795,740 units (SEC Form 4) (Amendment)